Nationwide Children's Hospital
700 Children's Drive
8 articles about Nationwide Children's Hospital
MAIA Biotechnology, Inc. Announces Research Collaboration with Nationwide Children’s Hospital to Evaluate THIO in Combination with Standard-of-Care Cancer Therapies
MAIA Biotechnology, Inc. , a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that MAIA has entered into a research and collaboration agreement with the Nationwide Children’s Hospital to evaluate the potential of THIO in combination with current standard-of-care therapies for cancer.
The concept is based on scientific studies showing that modulating the gut microbiome affects human health in multiple ways, beyond the expected gastrointestinal effects.
Parent Project Muscular Dystrophy Awards $148,000 in Grants to Nationwide Children's Hospital and University of Missouri to Improve Cardiac Function in Duchenne Muscular Dystrophy
Grants from Leading Duchenne Organization Are Result of Community Fundraising Effort to Support Cardiac Priorities in Duchenne
Late Monday the federal government charged the husband and wife team of Yu Zhou, 49, and Li Chen, 46, with theft of scientific trade secrets from the hospital that focused on exosomes and exosome isolation.
Hyundai Hope On Wheels Presents Nationwide Children's Hospital With $100,000 Hyundai Impact Award Grant To Support Pediatric Cancer Research
The Hyundai Hope On Wheels non-profit embarks on a nationwide tour this Summer to award new grants for pediatric cancer, surpassing $160 million in lifetime funding for research
Sarepta struck a deal with the Research Institute at Nationwide Children’s Hospital for the gene therapy candidate, calpain 3.
MORE Health Announces Agreement with Nationwide Children's Hospital
MORE Health, a global healthcare company, has entered into an agreement with Nationwide Children's Hospital in Columbus, OH, that will give pediatric patients access to the expertise and services of Nationwide Children's through MORE Health's Physician Collaboration Platform™.
San Francisco-based Audentes Therapeutics signed a licensing agreement and collaboration deal with Nationwide Children’s Hospital to expand its pipeline for vectorized antisense treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).